�The Medicines Company (NASDAQ: MDCO) announced that the U.S. Food and Drug Administration (FDA) has approved the intravenous (IV) therapy CleviprexTM (clevidipine butyrate) injectable emulsion for the decrease of rakehell pressure when oral therapy is not feasible or not worthy.
Cleviprex, a novel IV antihypertensive, represents an advancement over currently available therapies, providing
